Abstract
Cancer Targeting Gene-Viro-Therapy (CTGVT) and Gene Armed Oncolytic Virus Therapy (GAOVT) both are identical by inserting an antitumor gene into an oncolytic virus. This approach has gradually become a hot topic in cancer therapy, because that CTGVT (GAOVT) has much higher antitumor than that of either gene therapy alone or oncolytic virotherapy alone. We proposed the CTGVT strategy in 1999-2001, insisted it as a long term systematic approach to be examined over 10 years and have published 68 SCI papers some in good Journals. The CD gene armed oncolytic adenovirus therapy (GAOVT) for cancer treatment with potent antitumor effect was also named in our laboratory in 2003. Several modifications to CTGVT will be carried out by our group and will be introduced briefly in this paper. Most importantly, the modifications of CTGVT usually resulted in complete eradication of xenograft tumors in nude mice. In future best antitumor drugs may emerge from the modified CTGVT strategy and not from either gene therapy or virotherapy alone.
Keywords: Cancer therapy, Cancer targeting, Gene Viro-Therapy, Trend of gene therapy, Trend of virotherapy, Gene Armed Oncolytic Virus Therapy (GAOVT), oncolytic virotherapy, cancer, xenograft tumors, melanoma
Current Pharmaceutical Biotechnology
Title:Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Volume: 13 Issue: 9
Author(s): Xin -Yuan Liu, Hua -Guang Li, Kang -Jian Zhang and Jin -Fa Gu
Affiliation:
Keywords: Cancer therapy, Cancer targeting, Gene Viro-Therapy, Trend of gene therapy, Trend of virotherapy, Gene Armed Oncolytic Virus Therapy (GAOVT), oncolytic virotherapy, cancer, xenograft tumors, melanoma
Abstract: Cancer Targeting Gene-Viro-Therapy (CTGVT) and Gene Armed Oncolytic Virus Therapy (GAOVT) both are identical by inserting an antitumor gene into an oncolytic virus. This approach has gradually become a hot topic in cancer therapy, because that CTGVT (GAOVT) has much higher antitumor than that of either gene therapy alone or oncolytic virotherapy alone. We proposed the CTGVT strategy in 1999-2001, insisted it as a long term systematic approach to be examined over 10 years and have published 68 SCI papers some in good Journals. The CD gene armed oncolytic adenovirus therapy (GAOVT) for cancer treatment with potent antitumor effect was also named in our laboratory in 2003. Several modifications to CTGVT will be carried out by our group and will be introduced briefly in this paper. Most importantly, the modifications of CTGVT usually resulted in complete eradication of xenograft tumors in nude mice. In future best antitumor drugs may emerge from the modified CTGVT strategy and not from either gene therapy or virotherapy alone.
Export Options
About this article
Cite this article as:
Liu Xin -Yuan, Li Hua -Guang, Zhang Kang -Jian and Gu Jin -Fa, Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958869
DOI https://dx.doi.org/10.2174/138920112800958869 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets Troika of the Mouse Blastocyst: Lineage Segregation and Stem Cells
Current Stem Cell Research & Therapy Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design FLT3 Inhibition in Acute Myeloid Leukaemia – Current Knowledge and Future Prospects
Current Cancer Drug Targets